A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study.
Sign Up to like & getrecommendations! Published in 2018 at "European urology focus"
DOI: 10.1016/j.euf.2018.08.016
Abstract: The Immunotherapy to Prevent Progression on Active Surveillance Study is the first trial of immunotherapy for localized prostate cancer. We randomized active surveillance patients to PSA-TRICOM (PROSTVAC) or placebo for 5mo. Final results will be… read more here.
Keywords: active surveillance; immunotherapy; prevent progression; immunotherapy prevent ... See more keywords
Early progression to active tuberculosis is a highly heritable trait driven by 3q23 in Peruvians
Sign Up to like & getrecommendations! Published in 2019 at "Nature Communications"
DOI: 10.1038/s41467-019-11664-1
Abstract: Of the 1.8 billion people worldwide infected with Mycobacterium tuberculosis, 5–15% will develop active tuberculosis (TB). Approximately half will progress to active TB within the first 18 months after infection, presumably because they fail to… read more here.
Keywords: active tuberculosis; tuberculosis highly; progression active; progression ... See more keywords